NO20032531L - Tetralon-derivater som antitumormidler - Google Patents

Tetralon-derivater som antitumormidler

Info

Publication number: NO20032531L
Authority: NO; Norway
Prior art keywords: alkyl; amino; hydrogen; compounds; alkylene chain
Prior art date: 2000-12-07

Application number

NO20032531A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032531D0 (no

Inventor

Guy Georges

Adelbert Grossmann

Tim Sattelkau

Wolfgang Schaefer

Ulrich Tibes

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-07

Filing date

2003-06-04

Publication date

2003-06-04

2003-06-04 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-06-04 Publication of NO20032531D0 publication Critical patent/NO20032531D0/no

2003-06-04 Publication of NO20032531L publication Critical patent/NO20032531L/no

Links

XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical class C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 4
-1 trifluoromethyl- Chemical group 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
125000002947 alkylene group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
102000003964 Histone deacetylase Human genes 0.000 abstract 1
108090000353 Histone deacetylase Proteins 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20032531A 2000-12-07 2003-06-04 Tetralon-derivater som antitumormidler NO20032531L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00126820		2000-12-07
PCT/EP2001/014311 WO2002046144A1 (en)	2000-12-07	2001-12-06	Tetralone derivatives as antitumor agents

Publications (2)

Publication Number	Publication Date
NO20032531D0 NO20032531D0 (no)	2003-06-04
NO20032531L true NO20032531L (no)	2003-06-04

Family

ID=8170594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032531A NO20032531L (no)	2000-12-07	2003-06-04	Tetralon-derivater som antitumormidler

Country Status (25)

Country	Link
US (1)	US6531472B2 (cs)
EP (1)	EP1349830A1 (cs)
JP (1)	JP4091431B2 (cs)
KR (1)	KR20030077551A (cs)
CN (1)	CN100340545C (cs)
AR (1)	AR035659A1 (cs)
AU (2)	AU1607402A (cs)
BG (1)	BG107889A (cs)
BR (1)	BR0115988A (cs)
CA (1)	CA2430355A1 (cs)
CZ (1)	CZ20031833A3 (cs)
EC (1)	ECSP034642A (cs)
HR (1)	HRP20030451A2 (cs)
HU (1)	HUP0400579A2 (cs)
IL (1)	IL156133A0 (cs)
MA (1)	MA26972A1 (cs)
MX (1)	MXPA03004947A (cs)
NO (1)	NO20032531L (cs)
NZ (1)	NZ526051A (cs)
PL (1)	PL365324A1 (cs)
RU (1)	RU2288220C2 (cs)
SK (1)	SK8512003A3 (cs)
WO (1)	WO2002046144A1 (cs)
YU (1)	YU45803A (cs)
ZA (1)	ZA200304262B (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6822267B1 (en) *	1997-08-20	2004-11-23	Advantest Corporation	Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) *	2001-09-27	2004-03-16	The Regents Of The University Of Colorado	Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (en) *	2001-10-16	2011-07-27	Sloan-Kettering Institute For Cancer Research	Treatment of neurodegenerative diseases and cancer of the brain
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en)	2002-03-04	2006-12-12	Merck Hdac Research, Llc	Methods of treating mesothelioma with suberoylanilide hydroxamic acid
MXPA04008577A (es)	2002-03-04	2005-07-13	Aton Pharma Inc	Metodos para inducir diferenciacion terminal.
WO2003083067A2 (en) *	2002-03-28	2003-10-09	Brigham And Women's Hospital, Inc.	Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
EP1492596A1 (en) *	2002-04-05	2005-01-05	Fujisawa Pharmaceutical Co., Ltd.	Depsipeptide for therapy of kidney cancer
JP2005530734A (ja) *	2002-04-15	2005-10-13	スローン − ケッタリングインスティチュートフォーキャンサーリサーチ	癌の処置のための併用療法
GB0217777D0 (en) *	2002-07-31	2002-09-11	Novartis Ag	Organic compounds
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7250514B1 (en)	2002-10-21	2007-07-31	Takeda San Diego, Inc.	Histone deacetylase inhibitors
CA2508052A1 (en) *	2002-12-05	2004-06-17	Imperial College Innovations Limited	Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
US7375228B2 (en) *	2003-03-17	2008-05-20	Takeda San Diego, Inc.	Histone deacetylase inhibitors
HRP20060080A2 (en)	2003-08-26	2006-07-31	Sloan-Kettering Institute For Cancer Research	Method of treating cancer with hdac inhibitors
CN102349927A (zh)	2003-08-29	2012-02-15	Hdac默克研究有限责任公司	联合治疗癌症的方法
WO2005065681A1 (en) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) *	2003-12-19	2005-06-23	Syrrx, Inc.	Histone deacetylase inhibitors
CA2561954A1 (en) *	2004-04-05	2005-10-20	Myogen, Inc.	Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
US20070207120A1 (en) *	2004-04-14	2007-09-06	Sarah Drayton	Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
KR100632800B1 (ko)	2004-10-21	2006-10-16	한국화학연구원	히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
US7642275B2 (en) *	2004-12-16	2010-01-05	Takeda San Diego, Inc.	Histone deacetylase inhibitors
JP2008540574A (ja) *	2005-05-11	2008-11-20	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
TWI365068B (en)	2005-05-20	2012-06-01	Merck Sharp & Dohme	Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2615105A1 (en) *	2005-07-14	2007-01-25	Takeda San Diego, Inc.	Histone deacetylase inhibitors
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
EP1976835A2 (en) *	2006-01-13	2008-10-08	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US9539303B2 (en)	2006-04-24	2017-01-10	Celgene Corporation	Treatment of Ras-expressing tumors
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2015051035A1 (en)	2013-10-01	2015-04-09	The J. David Gladstone Institutes	Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3062783B1 (en)	2013-10-18	2020-08-12	The General Hospital Corporation	Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3461488A1 (en)	2017-09-27	2019-04-03	Onxeo	Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en)	2017-09-27	2019-04-03	Onxeo	Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TWI799691B (zh) *	2019-03-29	2023-04-21	景凱生物科技股份有限公司	具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
EP4405680A1 (en)	2021-09-20	2024-07-31	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20250213523A1 (en)	2022-04-05	2025-07-03	Istituto Nazionale Tumori Irccs - Fondazione G. Pascale	Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
WO2025026925A1 (en)	2023-07-28	2025-02-06	Ospedale San Raffaele S.R.L.	Gtf2i inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4448730A (en) *	1981-03-24	1984-05-15	Riet Bartholomeus Van T	Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) *	1985-01-30	1986-08-08	Teruhiko Beppu	制癌剤
US5369108A (en)	1991-10-04	1994-11-29	Sloan-Kettering Institute For Cancer Research	Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) *	1993-10-28	1997-06-10	Lockheed Corporation	Thermally energized electrical power source
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds

2001
- 2001-11-27 AR ARP010105504A patent/AR035659A1/es not_active Application Discontinuation
- 2001-12-04 US US10/006,173 patent/US6531472B2/en not_active Expired - Fee Related
- 2001-12-06 RU RU2003119658/04A patent/RU2288220C2/ru active
- 2001-12-06 BR BR0115988-7A patent/BR0115988A/pt not_active IP Right Cessation
- 2001-12-06 CA CA002430355A patent/CA2430355A1/en not_active Abandoned
- 2001-12-06 AU AU1607402A patent/AU1607402A/xx active Pending
- 2001-12-06 YU YU45803A patent/YU45803A/sh unknown
- 2001-12-06 HU HU0400579A patent/HUP0400579A2/hu unknown
- 2001-12-06 SK SK851-2003A patent/SK8512003A3/sk unknown
- 2001-12-06 IL IL15613301A patent/IL156133A0/xx unknown
- 2001-12-06 CN CNB018197345A patent/CN100340545C/zh not_active Expired - Fee Related
- 2001-12-06 MX MXPA03004947A patent/MXPA03004947A/es active IP Right Grant
- 2001-12-06 CZ CZ20031833A patent/CZ20031833A3/cs unknown
- 2001-12-06 EP EP01999552A patent/EP1349830A1/en not_active Withdrawn
- 2001-12-06 JP JP2002547883A patent/JP4091431B2/ja not_active Expired - Fee Related
- 2001-12-06 WO PCT/EP2001/014311 patent/WO2002046144A1/en not_active Ceased
- 2001-12-06 NZ NZ526051A patent/NZ526051A/xx unknown
- 2001-12-06 PL PL01365324A patent/PL365324A1/xx not_active Application Discontinuation
- 2001-12-06 KR KR10-2003-7007640A patent/KR20030077551A/ko not_active Ceased
- 2001-12-06 HR HR20030451A patent/HRP20030451A2/hr not_active Application Discontinuation
- 2001-12-06 AU AU2002216074A patent/AU2002216074C1/en not_active Ceased
2003
- 2003-05-30 ZA ZA200304262A patent/ZA200304262B/en unknown
- 2003-06-04 MA MA27193A patent/MA26972A1/fr unknown
- 2003-06-04 NO NO20032531A patent/NO20032531L/no not_active Application Discontinuation
- 2003-06-05 EC EC2003004642A patent/ECSP034642A/es unknown
- 2003-06-06 BG BG107889A patent/BG107889A/bg unknown

Also Published As

Publication number	Publication date
KR20030077551A (ko)	2003-10-01
NZ526051A (en)	2004-12-24
EP1349830A1 (en)	2003-10-08
JP4091431B2 (ja)	2008-05-28
CZ20031833A3 (cs)	2004-02-18
CN1478072A (zh)	2004-02-25
AU2002216074B2 (en)	2006-01-05
RU2288220C2 (ru)	2006-11-27
WO2002046144A1 (en)	2002-06-13
HRP20030451A2 (en)	2005-04-30
AU1607402A (en)	2002-06-18
ECSP034642A (es)	2003-07-25
SK8512003A3 (en)	2004-04-06
US20020065282A1 (en)	2002-05-30
MA26972A1 (fr)	2004-12-20
US6531472B2 (en)	2003-03-11
PL365324A1 (en)	2004-12-27
YU45803A (sh)	2006-05-25
CA2430355A1 (en)	2002-06-13
NO20032531D0 (no)	2003-06-04
HUP0400579A2 (hu)	2004-06-28
JP2004515488A (ja)	2004-05-27
IL156133A0 (en)	2003-12-23
BR0115988A (pt)	2004-01-13
MXPA03004947A (es)	2003-09-10
AU2002216074C1 (en)	2006-12-07
AR035659A1 (es)	2004-06-23
CN100340545C (zh)	2007-10-03
BG107889A (bg)	2004-06-30
ZA200304262B (en)	2004-08-30
HK1060875A1 (en)	2004-08-27

Legal Events

Date	Code	Title	Description
2006-07-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
YU45803A (sh)	2006-05-25	Tetralon derivati kao sredstva protiv tumora
Snieckus et al.	1990	Intramolecular. alpha.-amidoyl-to-aryl 1, 5-hydrogen atom transfer reactions. Heteroannulation and. alpha.-nitrogen functionalization by radical translocation
DE60304059D1 (de)	2006-05-11	3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
MXPA04005350A (es)	2004-09-27	Compuesto de dibencilamina, y uso medicinal del mismo.
NO973198L (no)	1997-07-09	Aryl- og heteroarylpurinforbindelser
MY131297A (en)	2007-08-30	Herbicides
BR0315405A (pt)	2005-08-09	Compostos inibidores da integrase tricìclica pré-organizados
YU20199A (sh)	2001-09-28	Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora
NO980154L (no)	1998-03-10	Sykliske GMP-spesifikke fosfodiesteraseinhibitorer
HUP0402454A2 (hu)	2005-03-29	Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2005092858A3 (en)	2006-03-02	Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
HUP0002353A2 (hu)	2001-05-28	IV típusú foszfodiészteráz inhibitor hatású 1-cikloalkil-1,8-naftiridin-4-on-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
GB1457385A (en)	1976-12-01	Substituted formamidines process for their preparation and their use as uv stabilisers
BR0308785A (pt)	2005-01-11	Derivados de alcoxipiridina
PL1601653T3 (pl)	2009-07-31	Sposób wytwarzania podstawionych estrów kwasu nikotynowego
DK534381A (da)	1982-06-06	Fremgangsmaade til fremstilling af 2-oxoazetidinderivater
DK0656001T3 (da)	2000-04-03	Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
ES8206462A1 (es)	1982-08-16	Un metodo para preparar derivados de 2-oxoazetidina.
GB1428226A (en)	1976-03-17	Process for the prepataion of aromatic hydroxylamines in the presence of catalysts
GB1458753A (en)	1976-12-15	Process for the preparation of aromatic hydroxylamines by hydro genation of aromatic nitro derivatives
ES2101887T3 (es)	1997-07-16	Procedimiento microbiologico para la hidroxilacion de acidos carboxilicos con heterociclo nitrogenado.
ES419661A1 (es)	1976-04-01	Un procedimiento de preparacion de hidrazonas.
GB1054655A (cs)
MX9800705A (es)	1998-10-31	Compuestos heterociclicos, composiciones para tratar isquemia de miocardio que los contiene, y procedimiento para su preparacion.
NO955071D0 (no)	1995-12-14	abeo-Ergolin-derivater som 5HT1A-ligander